The roles of GRK2, GRK3 and GRK5 in the heart and in the response to chronic beta-agonist treatment.
Publication
, Conference
Richmond, ME; Keys, JR; Alexander, MR; Blaxall, BC; Koch, WJ
Published in: FASEB JOURNAL
2001
Duke Scholars
Published In
FASEB JOURNAL
ISSN
0892-6638
Publication Date
2001
Volume
15
Issue
4
Start / End Page
A478 / A478
Related Subject Headings
- Biochemistry & Molecular Biology
- 3208 Medical physiology
- 3101 Biochemistry and cell biology
- 1116 Medical Physiology
- 0606 Physiology
- 0601 Biochemistry and Cell Biology
Citation
APA
Chicago
ICMJE
MLA
NLM
Richmond, M. E., Keys, J. R., Alexander, M. R., Blaxall, B. C., & Koch, W. J. (2001). The roles of GRK2, GRK3 and GRK5 in the heart and in the response to chronic beta-agonist treatment. In FASEB JOURNAL (Vol. 15, pp. A478–A478).
Richmond, M. E., J. R. Keys, M. R. Alexander, B. C. Blaxall, and W. J. Koch. “The roles of GRK2, GRK3 and GRK5 in the heart and in the response to chronic beta-agonist treatment.” In FASEB JOURNAL, 15:A478–A478, 2001.
Richmond ME, Keys JR, Alexander MR, Blaxall BC, Koch WJ. The roles of GRK2, GRK3 and GRK5 in the heart and in the response to chronic beta-agonist treatment. In: FASEB JOURNAL. 2001. p. A478–A478.
Richmond, M. E., et al. “The roles of GRK2, GRK3 and GRK5 in the heart and in the response to chronic beta-agonist treatment.” FASEB JOURNAL, vol. 15, no. 4, 2001, pp. A478–A478.
Richmond ME, Keys JR, Alexander MR, Blaxall BC, Koch WJ. The roles of GRK2, GRK3 and GRK5 in the heart and in the response to chronic beta-agonist treatment. FASEB JOURNAL. 2001. p. A478–A478.
Published In
FASEB JOURNAL
ISSN
0892-6638
Publication Date
2001
Volume
15
Issue
4
Start / End Page
A478 / A478
Related Subject Headings
- Biochemistry & Molecular Biology
- 3208 Medical physiology
- 3101 Biochemistry and cell biology
- 1116 Medical Physiology
- 0606 Physiology
- 0601 Biochemistry and Cell Biology